Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS - Free Report) in a research report report published on Monday. The brokerage issued a sell rating on the biotechnology company's stock.

A number of other analysts have also recently weighed in on the stock. JMP Securities reissued a market outperform rating and set a $6.00 price objective on shares of Cellectis in a report on Friday, May 31st. Oppenheimer lowered their target price on shares of Cellectis from $11.00 to $10.00 and set an outperform rating on the stock in a research report on Wednesday, June 12th.

Cellectis Stock Performance

CLLS stock remained flat at $2.40 during midday trading on Monday. 15,200 shares of the company's stock were exchanged, compared to its average volume of 50,524. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.39. Cellectis has a 12 month low of $0.96 and a 12 month high of $3.77. The company's fifty day moving average price is $2.12 and its 200-day moving average price is $2.46. The company has a market capitalization of $133.39 million, a P/E ratio of -1.86 and a beta of 3.10.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.05. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. The company had revenue of $9.50 million for the quarter, compared to analysts' expectations of $6.00 million. On average, research analysts anticipate that Cellectis will post -0.54 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

A number of hedge funds have recently modified their holdings of CLLS. Principal Financial Group Inc. grew its position in shares of Cellectis by 6.2% during the first quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company's stock worth $1,125,000 after acquiring an additional 24,906 shares during the last quarter. Baillie Gifford & Co. grew its position in shares of Cellectis by 1.3% during the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company's stock worth $2,192,000 after acquiring an additional 10,605 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Cellectis during the second quarter worth approximately $29,000. Finally, Long Focus Capital Management LLC grew its position in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock valued at $8,634,000 after buying an additional 130,000 shares during the last quarter. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.